IL300727A - Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis - Google Patents

Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis

Info

Publication number
IL300727A
IL300727A IL300727A IL30072723A IL300727A IL 300727 A IL300727 A IL 300727A IL 300727 A IL300727 A IL 300727A IL 30072723 A IL30072723 A IL 30072723A IL 300727 A IL300727 A IL 300727A
Authority
IL
Israel
Prior art keywords
cells
bvax
tumor
cell
mice
Prior art date
Application number
IL300727A
Other languages
English (en)
Inventor
Davin S Yoon
Alicia Regueiro-Ren
Andrew P Degnan
Gang Wu
Original Assignee
Bristol Myers Squibb Co
Davin S Yoon
Regueiro Ren Alicia
Andrew P Degnan
Gang Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Davin S Yoon, Regueiro Ren Alicia, Andrew P Degnan, Gang Wu filed Critical Bristol Myers Squibb Co
Publication of IL300727A publication Critical patent/IL300727A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL300727A 2020-08-19 2021-08-18 Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis IL300727A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063067452P 2020-08-19 2020-08-19
PCT/US2021/046420 WO2022040259A1 (en) 2020-08-19 2021-08-18 Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
IL300727A true IL300727A (en) 2023-04-01

Family

ID=77693624

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300727A IL300727A (en) 2020-08-19 2021-08-18 Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis

Country Status (14)

Country Link
US (1) US12486267B2 (cg-RX-API-DMAC10.html)
EP (1) EP4200297B1 (cg-RX-API-DMAC10.html)
JP (1) JP7813775B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230053644A (cg-RX-API-DMAC10.html)
CN (1) CN116096717B (cg-RX-API-DMAC10.html)
AR (1) AR123281A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021328575A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002737A2 (cg-RX-API-DMAC10.html)
CA (1) CA3190065A1 (cg-RX-API-DMAC10.html)
ES (1) ES3071068T3 (cg-RX-API-DMAC10.html)
IL (1) IL300727A (cg-RX-API-DMAC10.html)
MX (1) MX2023001885A (cg-RX-API-DMAC10.html)
TW (1) TW202227432A (cg-RX-API-DMAC10.html)
WO (1) WO2022040259A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
KR20240148413A (ko) * 2022-02-18 2024-10-11 브리스톨-마이어스 스큅 컴퍼니 Tlr9의 억제제로서 유용한 치환된 비시클릭 헤테로아릴 화합물
CN120230100B (zh) * 2025-05-30 2025-09-05 中国药科大学 一种咪唑并[1,2-a]吡嗪或咪唑并[1,2-a]吡啶类化合物及其医药用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235037A1 (en) 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
JP2009532501A (ja) 2006-04-04 2009-09-10 ミリアド ジェネティクス， インコーポレイテッド 疾患および障害のための化合物
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
EP2340243B1 (en) 2008-10-17 2014-10-08 Boehringer Ingelheim International GmbH Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
BR112012006630A2 (pt) 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
EP2757883B1 (en) 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US20130158049A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 7-azaindole inhibitors of crac
US20130158066A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
WO2013156431A1 (en) 2012-04-17 2013-10-24 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives
WO2013191113A1 (ja) 2012-06-18 2013-12-27 住友化学株式会社 縮合複素環化合物
US9643967B2 (en) 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
EP3194394B1 (en) * 2014-09-16 2019-01-09 Syngenta Participations AG Pesticidally active tetracyclic derivatives with sulphur containing substituents
CA2999852A1 (en) 2015-09-29 2017-04-06 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting suv39h2
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CN109715617B (zh) 2016-07-30 2022-04-19 百时美施贵宝公司 作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物
ES2902504T3 (es) 2016-09-09 2022-03-28 Bristol Myers Squibb Co Compuestos de indol sustituidos con piridilo
US11370794B2 (en) * 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
WO2018165112A1 (en) 2017-03-09 2018-09-13 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting histone methyltransferase
EP3661926B1 (en) 2017-08-04 2022-02-23 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of tlr7/8/9
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
EA202091474A1 (ru) 2017-12-19 2020-11-18 Бристол-Маерс Сквибб Компани Замещенные индольные соединения, применимые в качестве ингибиторов tlr
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
JP7287967B2 (ja) 2017-12-20 2023-06-06 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有効なアミノインドール化合物
EA202091530A1 (ru) 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
EP4089096A4 (en) 2020-01-09 2024-01-03 Sumitomo Chemical Company, Limited HETEROCYCLIC COMPOUND AND MEANS THEREOF FOR CONTROLLING HARMFUL ARTHROPODS

Also Published As

Publication number Publication date
EP4200297B1 (en) 2026-05-13
JP7813775B2 (ja) 2026-02-13
CN116096717B (zh) 2026-04-10
ES3071068T3 (en) 2026-06-19
TW202227432A (zh) 2022-07-16
AR123281A1 (es) 2022-11-16
WO2022040259A1 (en) 2022-02-24
AU2021328575A1 (en) 2023-03-16
US20240067638A1 (en) 2024-02-29
EP4200297A1 (en) 2023-06-28
KR20230053644A (ko) 2023-04-21
MX2023001885A (es) 2023-03-10
BR112023002737A2 (pt) 2023-03-14
EP4200297C0 (en) 2026-05-13
CA3190065A1 (en) 2022-02-24
US12486267B2 (en) 2025-12-02
CN116096717A (zh) 2023-05-09
JP2023538393A (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
Lee-Chang et al. Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma
Lemke-Miltner et al. Antibody opsonization of a TLR9 agonist–containing virus-like particle enhances in situ immunization
KR20150030750A (ko) 정상 b 세포를 고갈시켜 내성을 유도하기 위한 ｃａｒｔ19의 용도
JP2018513165A (ja) Ｍｖａ又はｍｖａδｅ３ｌの固形腫瘍免疫療法剤としての使用
US20250186582A1 (en) Methods for detecting and reversing immune therapy resistance
US8685640B2 (en) Medical methods and agents for use therein
HK1257690A1 (zh) 用小分子消融化合物离体增强免疫细胞活性进行癌症免疫治疗的方法
Lozupone et al. Adoptive transfer of an anti‐MART‐127–35‐specific CD8+ T cell clone leads to immunoselection of human melanoma antigen‐loss variants in SCID mice
JP2021535083A (ja) Ｃｄ８０細胞外ドメインｆｃ融合タンパク質投与レジメン
WO2020160090A1 (en) Whole cell tumor vaccines and methods of use thereof
WO2017177063A1 (en) Use of heterodimeric il-15 in adoptive cell transfer
Wollenberg et al. Gene therapy-phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol
US20240209313A1 (en) B-cell based immunotherapy for the treatment of glioblastoma and other cancers
WO2022241475A1 (en) Targeting extracellular matrix proteins to regulate nk cell function in peripheral tissues
KR20230044315A (ko) 췌장 암 평가 및 치료를 위한 방법 및 조성물
Zhong et al. TLR7 stimulation augments T effector‐mediated rejection of skin expressing neo‐self antigen in keratinocytes
Pattanayak et al. Inhibition of KDEL receptors remodels the tumor microenvironment for robust T cell independent tumor regression
Caponegro et al. Contributions of immune cell populations in the maintenance, progression, and therapeutic modalities of glioma
Tanwar Combination of Pre-existing and New Strategies to Improve CAR-T Cells’ Efficiency.
Agliardi Development of a Chimeric Antigen Receptor (CAR)-based T cell therapy for glioblastoma
Donini Preclinical exploration of a novel cellular immunotherapy with CAR-redirected cytokine-induced killer lymphocytes (CIK) against soft tissue sarcomas
Shute Glycolipid-Loaded Nanoparticles Harness Invariant Natural Killer T Cells for Tumor Immunotherapy
WO2024102874A1 (en) Fenofibrate improves t-cell therapies
Fallatah Combination of immune stimulatory strategies to promote anti-tumour immunity
JP2024527963A (ja) ユニバーサル受容体免疫細胞療法